Sodium Gluconate, Gluconic Acid, and Derivative Products From the People's Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value, 47876-47879 [2018-20606]
Download as PDF
47876
Federal Register / Vol. 83, No. 184 / Friday, September 21, 2018 / Notices
they are affiliated with (if any), and an
email address prior to placing callers
into the conference call. Callers can
expect to incur charges for calls they
initiate over wireless lines, and the
Commission will not refund any
incurred charges. Callers will incur no
charge for calls they initiate over landline connections to the toll-free
telephone number. Persons with hearing
impairments may also follow the
proceedings by first calling the Federal
Relay Service at 1–800–977–8339 and
providing the Service with the
conference call number and conference
ID number.
Members of the public are also
entitled to submit written comments;
the comments must be received in the
regional office within 30 days following
the meeting. Written comments may be
mailed to the Regional Program Unit
Office, U.S. Commission on Civil Rights,
230 S. Dearborn, Suite 2120, Chicago, IL
60604. They may also be faxed to the
Commission at (312) 353–8324, or
emailed to Regional Director, Jeffrey
Hinton at jhinton@usccr.gov. Persons
who desire additional information may
contact the Regional Program Unite
Office at (312) 353–8311.
Records generated from this meeting
may be inspected and reproduced at the
Regional Program Unit, as they become
available, both before and after the
meeting. Records of the meeting will be
available via www.facadatabase.gov
under the Commission on Civil Rights,
South Carolina Advisory Committee
link. Persons interested in the work of
this Committee are directed to the
Commission’s website, https://
www.usccr.gov, or may contact the
Southern Regional Office at the above
email or street address.
Agenda
daltland on DSKBBV9HB2PROD with NOTICES
Welcome and Introductions
Dr. Geoffrey Alpert, University of South
Carolina, Department of Criminology
and Criminal Justice
Discussion on Policing Project
Open Comment
Adjournment
Dated: September 18, 2018.
David Mussatt,
Supervisory Chief, Regional Programs Unit.
[FR Doc. 2018–20596 Filed 9–20–18; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:30 Sep 20, 2018
Jkt 244001
DEPARTMENT OF COMMERCE
International Trade Administration
[A–570–071]
Sodium Gluconate, Gluconic Acid, and
Derivative Products From the People’s
Republic of China: Final Affirmative
Determination of Sales at Less Than
Fair Value
Enforcement and Compliance,
International Trade Administration,
Department of Commerce.
SUMMARY: The Department of Commerce
(Commerce) determines that sodium
gluconate, gluconic acid, and derivative
products from the People’s Republic of
China (China) are being sold in the
United States at less than fair value
(LTFV).
AGENCY:
DATES:
Applicable September 21, 2018.
FOR FURTHER INFORMATION CONTACT:
Magd Zalok or Stephen Bailey, AD/CVD
Operations, Office IV, Enforcement and
Compliance, International Trade
Administration, U.S. Department of
Commerce, 1401 Constitution Avenue
NW, Washington, DC 20230; telephone:
(202) 482–4162 or (202) 482–0193,
respectively.
SUPPLEMENTARY INFORMATION:
This final determination is made in
accordance with section 735(a) of the
Tariff Act of 1930, as amended (the Act).
On July 10, 2018, Commerce published
in the Federal Register its preliminary
affirmative determination of sales at
LTFV investigation of sodium
gluconate, gluconic acid, and derivative
products from China.1 We invited
interested parties to comment on the
Preliminary Determination. On August
9, 2018, we received a case brief from
PMP Fermentation Products, Inc., the
petitioner in this investigation. We
received no comments from other
interested parties.
For a complete description of the
events that followed the Preliminary
Determination, as well as a full
discussion of the issues raised by parties
for this final determination, see the
Issues and Decision Memorandum that
is dated concurrently with this
determination and hereby adopted by
this notice.2 The Issues and Decision
1 See Sodium Gluconate, Gluconic Acid, and
Derivative Products from the People’s Republic of
China: Preliminary Determination of Sales at Less
Than Fair Value, 83 FR 31949 (July 10, 2018)
(Preliminary Determination) and accompanying
Preliminary Decision Memorandum.
2 See Memorandum, ‘‘Issues and Decision
Memorandum for the Final Affirmative
Determination in the Less-Than-Fair-Value
Frm 00003
Fmt 4703
Sfmt 4703
Scope of the Investigation
The products covered by this
investigation are sodium gluconate,
gluconic acid, and derivative products
from China. For a complete description
of the scope of this investigation, see
Appendix I to this notice.
No interested party commented on the
scope published in the Preliminary
Determination. Thus, Commerce has
made no changes to the scope of the
investigation from that published in the
Initiation Notice and Preliminary
Determination.3
Period of Investigation
Background
PO 00000
Memorandum is a public document and
is on file electronically via Enforcement
and Compliance’s Antidumping and
Countervailing Duty Centralized
Electronic Service System (ACCESS).
ACCESS is available to registered users
at https://access.trade.gov, and is
available to all parties in the Central
Records Unit, Room B8024 of the main
Department of Commerce building. In
addition, a complete version of the
Issues and Decision Memorandum can
be accessed directly at https://
enforcement.trade.gov/frn/. The signed
Issues and Decision Memorandum and
the electronic version are identical in
content.
The period of investigation is April 1,
2017, through September 30, 2017.
Analysis of Comments Received
All issues raised in the case brief that
was submitted by the petitioner in this
investigation are addressed in the Issues
and Decision Memorandum. A list of
the issues addressed in the Issues and
Decision Memorandum is attached to
this notice at Appendix II.
China-Wide Entity
For the reasons explained in the
Preliminary Determination, we are
continuing to find that the use of
adverse facts available (AFA), pursuant
to sections 776(a) and (b) of the Act, is
appropriate and are applying a rate
based entirely on AFA to the Chinawide entity.4 The China-wide entity
includes Shandong Fuyang
Biotechnology Co., Ltd./Shandong
Fuyang Biology Starch Co., Ltd.
Investigation of Sodium Gluconate, Gluconic Acid,
and Derivative Products from the People’s Republic
of China’’ (Issues and Decision Memorandum).
3 See Sodium Gluconate, Gluconic Acid, and
Derivative Products from France and the People’s
Republic of China: Initiation of Less-ThanFairValue Investigations, 83 FR 516 (January 4,
2018) (Initiation Notice); Preliminary
Determination, 83 FR at 31949 and accompanying
Preliminary Decision Memorandum at 5–6.
4 See Preliminary Decision Memorandum at 11.
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 83, No. 184 / Friday, September 21, 2018 / Notices
(Shandong Fuyang),5 Qingdao Dongxiao
Enterprise Co., Ltd. (Qingdao
Dongxiao),6 Zhejiang Tianyi Food
Additives Co., Ltd. (Tianyi Food),7 and
Dezhou Huiyang Biotechnology Co.,
Ltd. (Dezhou Huiyang).8 These
companies failed to respond to
Commerce’s requests for information
and withdrew from participation in this
investigation. As these non-responsive
companies did not demonstrate that
they are eligible for separate rate status,
Commerce continues to consider them
to be part of the China-wide entity.
Consequently, we continue to find that
the China-wide entity, which includes
these non-responsive companies,
withheld requested information,
significantly impeded this proceeding
and failed to cooperate to the best of its
ability.
China-Wide Rate
daltland on DSKBBV9HB2PROD with NOTICES
In selecting the AFA rate for the
China-wide entity, Commerce’s practice
is to select a rate that is sufficiently
adverse to ensure that the uncooperative
party does not obtain a more favorable
result by failing to cooperate than if it
had fully cooperated.9 Specifically, it is
Commerce’s practice to select, as an
AFA rate, the higher of: (a) The highest
dumping margin alleged in the petition;
or (b) the highest calculated dumping
margin of any respondent in the
investigation.10 There are no
respondents for which we are
calculating a separate dumping margin
for the final determination. Thus, the
highest (and only) rate on the record of
the proceeding is the rate found in the
Petition,11 which is the only
information reasonably at Commerce’s
disposal to determine a rate that is
sufficiently adverse to induce
cooperation.12
Thus, as AFA, Commerce assigned to
the China-wide entity the rate of 213.15
percent, which is the sole dumping
margin alleged in the Petition.13
Separate Rates
For the final determination, we
continue to find that the evidence
placed on the record of this
investigation by Anhui Xingzhou
Medicine Food Co., Ltd. (Xingzhou
Medicine) 14 demonstrates an absence of
de jure and de facto government control.
Accordingly, consistent with its
Preliminary Determination, Commerce
assigned Xingzhou Medicine a separate
rate, which is the petition rate, because
it is the only rate available on the record
of this proceeding. For a full description
of the methodology underlying
Commerce’s final determination, see the
Issues and Decision Memorandum.
Combination Rates
In the Initiation Notice, Commerce
stated that it would calculate producer/
exporter combination rates for the
respondents that are eligible for a
separate rate in this investigation.15
Policy Bulletin 05.1 describes this
practice.16 Because Commerce
determined that the mandatory
respondents originally selected are not
eligible for separate rate status and,
thus, should be considered part of the
China-wide entity and assigned, as
AFA, the petition rate to the China-wide
entity, Commerce did not calculate
producer/exporter combination rates for
those respondents.
Final Determination
Commerce determines that sodium
gluconate, gluconic acid, and derivative
products from China are being, or are
likely to be, sold in the United States at
LTFV, and that the following dumping
margins exist:
Estimated
weightedaverage
dumping
margin
(percent)
Exporter
Producer
Anhui Xingzhou Medicine Food Co., Ltd ...................................
Anhui Xingzhou Medicine Food Co., Ltd ...................................
China-wide Entity 17 ....................................................................
Xiwang Pharmaceutical Co., Ltd ................................................
Zhucheng Shuguang Biotech Co., Ltd .......................................
.....................................................................................................
5 See Memorandum, ‘‘Less-Than-Fair-Value
Investigation of Sodium Gluconate, Gluconic Acid,
and Derivative Products from the People’s Republic
of China: Respondent Selection,’’ dated January 17,
2018 (Initial Respondent Selection Memorandum).
See also Shandong Fuyang letter, ‘‘Notice of NonParticipation in Investigation,’’ dated March 30,
2018.
6 See Qingdao Dongxiao’s Letter, ‘‘Withdrawal
from Participation,’’ dated February 14, 2018.
7 See Tianyi Food, see Commerce’s
Memorandum, ‘‘Selection of Additional
Respondent,’’ dated March 5, 2018 and Tianyi
Food’s Letter, ‘‘Withdrawal from Participation,’’
dated March 8, 2018.
8 See Dezhou Huiyang’s Commerce’s
Memorandum, ‘‘Selection of Additional
Respondent,’’ dated March 9, 2018 and Dezhou
Huiyang’s Letter, ‘‘Dezhou Huiyang Biotechnology
Co., Ltd. Withdrawal of Participation in
Antidumping Duty Investigation,’’ dated March 13,
2018.
9 See Statement of Administrative Action
accompanying the Uruguay Round Agreements Act,
H.R. Rep. No. 103–316 at 870 (1994) (H.R. Rep 103–
316), reprinted in 1994 U.S.C.A.A.N.
10 See Silicon Metal from Australia: Affirmative
Final Determination of Sales at Less Than Fair
Value and Final Affirmative Determination of
Critical Circumstances in Part, 83 FR 9839 (March
VerDate Sep<11>2014
17:30 Sep 20, 2018
Jkt 244001
8, 2018) and accompanying Issues and Decision
Memorandum at Comment 1.
11 See Petitioner’s Letter, ‘‘Petition for
Antidumping and Countervailing Duties: Sodium
Gluconate, Gluconic Acid, and Derivative Products
from the People’s Republic of China and France’’
(November 30, 2017) (the Petition).
12 See, e.g., Certain Hardwood Plywood Products
from the People’s Republic of China: Preliminary
Affirmative Determination of Sales at Less Than
Fair Value, Preliminary Affirmative Determination
of Critical Circumstances, in Part, 82 FR 28629
(June 23, 2017) and accompanying Preliminary
Decision Memorandum at pages 31–32 (revised in
Certain Hardwood Plywood Products from the
People’s Republic of China: Final Determination of
Sales at Less Than Fair Value, and Final
Affirmative Determination of Critical
Circumstances, in Part, 82 FR 53460 (November 16,
2017) because Commerce calculated a higher rate
than the highest Petition rate to apply as the AFA
rate)).
13 See Petitioner’s letter, ‘‘Petition for
Antidumping and Countervailing Duties: Sodium
Gluconate, Gluconic Acid, and Derivative Products
from the People’s Republic of China and France,’’
dated November 30, 2017 (the Petitions),
Sodium Gluconate, Gluconic Acid, and Derivative
Products from France and the People’s Republic of
China: Initiation of Less-Than-Fair-Value
Investigations, 83 FR 516 (January 4, 2018)
PO 00000
Frm 00004
Fmt 4703
Sfmt 4703
47877
213.15
213.15
213.15
(Initiation Notice), and Antidumping Duty
Investigation Initiation Checklist: Sodium
Gluconate, Gluconic Acid, and Derivative Products
from the People’s Republic of China, dated
December 20, 2017 (China AD Initiation Checklist).
14 See, e.g., Xingzhou Medicine’s Letter,
‘‘Xingzhou Medicine Separate Rate Application,’’
dated February 5, 2018; Commerce’s Letter, ‘‘1st
Supplemental Questionnaire Regarding the
Separate Rate Application for Anhui Xingzhou
Medicine Food Co., Ltd.,’’ dated February 27, 2018;
Xingzhou Medicine’s Letter, ‘‘Supplemental SRA
Questionnaire Response,’’ dated March 6, 2018;
Commerce’s Letter, ‘‘2nd Supplemental
Questionnaire regarding the Separate Rate
Application for Anhui Xingzhou Medicine Food
Co., Ltd.,’’ dated March 22, 2018. and Xingzhou
Medicine’s Letter, ‘‘Second Supplemental SRA
Questionnaire Response,’’ dated March 29, 2018.
15 See Initiation Notice, 83 FR 516.
16 See Enforcement and Compliance’s Policy
Bulletin No. 05.1, regarding, ‘‘Separate-Rates
Practice and Application of Combination Rates in
Antidumping Investigations involving Non-Market
Economy Countries,’’ (April 5, 2005) (Policy
Bulletin 05.1), available on Commerce’s website at
https://enforcement.trade.gov/policy/bull05-1.pdf.
17 The China-wide Entity includes Dezhou
Huiyang, Qingdao Dongxiao, Shandong Fuyang,
and Tianyi Food.
E:\FR\FM\21SEN1.SGM
21SEN1
47878
Federal Register / Vol. 83, No. 184 / Friday, September 21, 2018 / Notices
Disclosure
Normally, Commerce discloses to
interested parties the calculations
performed in connection with a final
determination within five days of any
public announcement or, if there is no
public announcement, within five days
of the date of publication of the notice
of final determination in the Federal
Register, in accordance with 19 CFR
351.224(b). However, because
Commerce applied AFA to the Chinawide entity (which includes the
companies subject to individual
examination) in this investigation, in
accordance with section 776 of the Act,
and the applied AFA rate is based solely
on the Petition, there are no calculations
to disclose.
daltland on DSKBBV9HB2PROD with NOTICES
Continuation of Suspension of
Liquidation
In accordance with section
735(c)(1)(B) of the Act, we will direct
U.S. Customs and Border Protection
(CBP) to continue to suspend
liquidation of all entries of sodium
gluconate, gluconic acid, and derivative
products from China, as described in
Appendix I of this notice, which are
entered, or withdrawn from warehouse,
for consumption on or after July 10,
2018, the date of publication in the
Federal Register of the affirmative
Preliminary Determination.
Further, pursuant to section
735(c)(1)(B)(ii) of the Act, Commerce
will instruct CBP to collect a cash
deposit as follows: (1) The rate for the
exporters listed in the chart above will
be the rate we have determined in this
final determination; (2) for all Chinese
exporters of subject merchandise which
have not received their own rate, the
cash-deposit rate will be the China-wide
rate; and (3) for all non-Chinese
exporters of subject merchandise which
have not received their own rate, the
cash-deposit rate will be the rate
applicable to the Chinese exporter/
producer combination that supplied that
non-Chinese exporter. These
suspension-of-liquidation instructions
will remain in effect until further notice.
Because there has been no
demonstration that an adjustment for
domestic subsidies is warranted,
Commerce has not made any such
adjustment to the rate assigned to
Xingzhou Medicine or the China-wide
entity. Additionally, Commerce is
making no adjustments for export
subsidies to the antidumping cash
deposit rate in this investigation
because we have made no findings in
the companion countervailing duty
VerDate Sep<11>2014
17:30 Sep 20, 2018
Jkt 244001
investigation that any of the programs
are export subsidies.18
International Trade Commission
Notification
In accordance with section 735(d) of
the Act, we intend to notify the
International Trade Commission (ITC) of
the final affirmative determination of
sales at LTFV. As Commerce’s final
determination is affirmative, in
accordance with section 735(b)(2) of the
Act, the ITC will determine, within 45
days, whether the domestic industry in
the United States is materially injured,
or threatened with material injury, by
reason of imports of sodium gluconate,
gluconic acid, and derivative products
from China, or sales (or the likelihood
of sales) for importation, of sodium
gluconate, gluconic acid, and derivative
products from China. If the ITC
determines that such injury does not
exist, this proceeding will be
terminated, and all securities posted
will be refunded or canceled. If the ITC
determines that such injury does exist,
Commerce intends to issue an
antidumping duty order directing CBP
to assess, upon further instruction by
Commerce, antidumping duties on all
imports of the subject merchandise
entered, or withdrawn from warehouse,
for consumption on or after the effective
date of the suspension of liquidation.
Notification Regarding Administrative
Protective Orders
This notice will serve as a reminder
to the parties subject to administrative
protective order (APO) of their
responsibility concerning the
disposition of propriety information
disclosed under APO in accordance
with 19 CFR 351.305. Timely written
18 See Sodium Gluconate, Gluconic Acid and
Derivative Products from the People’s Republic of
China: Preliminary Affirmative Countervailing Duty
Determination and Alignment of Final
Determination With Final Antidumping Duty
Determination, 83 FR 23888 (May 23, 2018)
(Preliminary Affirmative CVD Determination) and
accompanying Preliminary Determination
Memorandum at 19 (‘‘As AFA, pursuant to section
776(a) and (b), Commerce is finding all programs
initiated upon in this proceeding to be
countervailable—that is, they provide a financial
contribution within the meaning of sections
771(5)(B)(i) and (D) of the Act, confer a benefit
within the meaning of section 771(5)(B) of the Act,
and are specific within the meaning of section
771(5A) of the Act. Accordingly, all programs are
included in Commerce’s calculation of an AFA rate
for Fuyang, Hongyu Chemical, Kaison, and Qingdao
Dongxiao.’’) (emphasis added). In the final
determination of the companion countervailing
duty investigation, Commerce made no changes to
its analysis and calculations of subsidy rates from
the Preliminary Affirmative CVD Determination.
See Sodium Gluconate, Gluconic Acid and
Derivative Products from the People’s Republic of
China: Final Affirmative Countervailing Duty
Determination, and accompanying Issues and
Decision Memorandum.
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
notification of return or destruction of
APO materials or conversion to judicial
protective order is hereby requested.
Failure to comply with the regulations
and terms of an APO is a sanctionable
violation.
We intend to issue and publish this
determination in accordance with
sections 735(d) and 777(i)(1) of the Act.
Dated: September 17, 2018.
Gary Taverman,
Deputy Assistant Secretary for Antidumping
and Countervailing Duty Operations,
performing the non-exclusive functions and
duties of the Assistant Secretary for
Enforcement and Compliance.
Appendix I
Scope of the Investigation
The scope of the investigation covers all
grades of sodium gluconate, gluconic acid,
liquid gluconate, and glucono delta lactone
(GDL) (collectively GNA Products),
regardless of physical form (including, but
not limited to substrates; solutions; dry
granular form or powders, regardless of
particle size; or as a slurry). The scope also
includes GNA Products that have been
blended or are in solution with other
product(s) where the resulting mix contains
35 percent or more of sodium gluconate,
gluconic acid, liquid gluconate, and/or GDL
by dry weight.
Sodium gluconate has a molecular formula
of NaC6H11O7. Sodium gluconate has a
Chemical Abstract Service (CAS) registry
number of 527–07–1, and can also be called
‘‘sodium salt of gluconic acid’’ and/or
sodium 2, 3, 4, 5, 6 pentahydroxyhexanoate.
Gluconic acid has a molecular formula of
C6H12O7. Gluconic acid has a CAS registry
number of 526–95–4, and can also be called
2, 3, 4, 5, 6 pentahydroxycaproic acid. Liquid
gluconate is a blend consisting only of
gluconic acid and sodium gluconate in an
aqueous solution. Liquid gluconate has CAS
registry numbers of 527–07–1, 526–95–4, and
7732–18–5, and can also be called 2, 3, 4, 5,
6-pentahydroxycaproic acid-hexanoate. GDL
has a molecular formula of C6H10O6. GDL has
a CAS registry number of 90–80–2, and can
also be called d-glucono-1,5-lactone.
The merchandise covered by the scope of
the investigation is currently classified in the
Harmonized Tariff Schedule of the United
States (HTSUS) under subheadings
2918.16.1000, 2918.16.5010, and
2932.20.5020. Merchandise covered by the
scope may also enter under HTSUS
subheadings 2918.16.5050, 3824.99.2890,
and 3824.99.9295. Although the HTSUS
subheadings and CAS registry numbers are
provided for convenience and customs
purposes, the written description of the
merchandise is dispositive.
Appendix II
List of Topics Discussed in the Issues and
Decision Memorandum
I. Summary
II. List of Issues
III. Background
IV. Scope of Investigation
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 83, No. 184 / Friday, September 21, 2018 / Notices
V. Discussion of the Issues
Comment 1: Application of Adverse Facts
Available (AFA) to the China-wide
Entity
Comment 2: Whether to Assign the ChinaWide Entity Rate to the Separate Rate
Applicant
Comment 3: Whether the Scope of the
Investigation Should be Modified
VI. Recommendation
[FR Doc. 2018–20606 Filed 9–20–18; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
International Trade Administration
[C–570–072]
Sodium Gluconate, Gluconic Acid and
Derivative Products From the People’s
Republic of China: Final Affirmative
Countervailing Duty Determination
Enforcement and Compliance,
International Trade Administration,
Department of Commerce.
SUMMARY: The Department of Commerce
(Commerce) determines that
countervailable subsidies are being
provided to producers and exporters of
sodium gluconate, gluconic acid and
derivative products from the People’s
Republic of China (China).
DATES: Applicable September 21, 2018.
FOR FURTHER INFORMATION CONTACT:
Robert Galantucci or Jonathan Hill, AD/
CVD Operations, Office IV, Enforcement
and Compliance, International Trade
Administration, U.S. Department of
Commerce, 1401 Constitution Avenue
NW, Washington, DC 20230; telephone
(202) 482–2923 or (202) 482–3518,
respectively.
AGENCY:
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
Background
This final determination is made in
accordance with section 705 of the
Tariff Act of 1930, as amended (the Act).
The petitioner in this investigation is
PMP Fermentation Products, Inc. (the
petitioner). The mandatory respondents
in this investigation are Qingdao
Dongxiao Enterprise Co., Ltd. (Qingdao
Dongxiao), Shandong Fuyang
Biotechnology Co. (Fuyang), Shandong
Kaison Biochemical Co Ltd (Kaison),
and Tongxiang Hongyu Chemical Co.,
Ltd. (Hongyu Chemical). Hongyu
Chemical, Kaison, and Qingdao
Dongxiao did not respond to any of our
requests for information.
We published our Preliminary
Determination on May 23, 2018.1 On
1 See Sodium Gluconate, Gluconic Acid, and
Derivative Products from the People’s Republic of
China: Preliminary Affirmative Countervailing Duty
VerDate Sep<11>2014
17:30 Sep 20, 2018
Jkt 244001
May 30, 2018, Fuyang, the sole
respondent to provide a questionnaire
response in this investigation, notified
Commerce that it would no longer be
participating in the proceeding.2 On
June 21, 2018, the petitioner submitted
a case brief.3 We received no comments
from other interested parties.
Additional background on this case,
including a summary of events that
occurred since Commerce published the
Preliminary Determination, and a
discussion of comments from the
petitioner, are provided in the Issues
and Decision Memorandum, which is
hereby adopted by this notice.4 The
Issues and Decision Memorandum is a
public document and is on file
electronically via Enforcement and
Compliance’s Antidumping and
Countervailing Duty Centralized
Electronic Service System (ACCESS).
ACCESS is available to registered users
at https://access.trade.gov and is
available to all parties in the Central
Records Unit, room B8024 of the main
Department of Commerce building. In
addition, a complete version of the
Issues and Decision Memorandum can
be accessed directly at https://
enforcement.trade.gov. The signed and
electronic versions of the Issues and
Decision Memorandum are identical in
content.
Scope of the Investigation
The products covered by this
investigation are sodium gluconate,
gluconic acid, and derivative products
from China. We have made no changes
to the scope of the investigation, as
published in the Preliminary
Determination.5 For a complete
description of the scope of this
Determination and Alignment of Final
Determination with Final Antidumping Duty
Determination, 83 FR 23888 (May 23, 2018)
(Preliminary Determination) and accompanying
Preliminary Decision Memorandum.
2 See Letter from Fuyang, ‘‘Countervailing Duty
Investigation on Sodium Gluconate, Gluconic Acid,
and Derivative Products from the People’s Republic
of China: Notice of Non-Participation in
Investigation,’’ dated May 30, 2018.
3 See Letter from the petitioner, ‘‘Countervailing
Duty Investigation of Sodium Gluconate, Gluconic
Acid and Derivative Products from the People’s
Republic of China: Petitioner’s Case Brief,’’ dated
June 21, 2018.
4 See Memorandum, ‘‘Issues and Decision
Memorandum for the Final Affirmative
Determination in the Countervailing Duty
Investigation of Sodium Gluconate, Gluconic Acid
and Derivative Products from the People’s Republic
of China,’’ dated concurrently with, and hereby
adopted by, this notice (Issues and Decision
Memorandum).
5 See 83 FR at 23888 (noting that Commerce
would consider scope comments from interested
parties and implement any changes to the scope in
the final countervailing duty determination).
PO 00000
Frm 00006
Fmt 4703
Sfmt 4703
47879
investigation, see Appendix I to this
notice.
Period of Investigation
The period of investigation is January
1, 2016, through December 31, 2016.
Analysis of Comments Received
All issues raised in the case brief
submitted by the petitioner are
addressed in the Issues and Decision
Memorandum accompanying this
notice. A list of the issues addressed in
the memorandum is attached to this
notice at Appendix II.
Adverse Facts Available
In this final determination, we
continue to apply facts available with an
adverse inference to Fuyang, Hongyu
Chemical, Kaison, and Qingdao
Dongxiao. For purposes of this final
determination, we relied on facts
available and, because the respondents
did not respond, or did not act to the
best of their ability in responding to, our
requests for information, we drew
adverse inferences in selecting from
among the facts otherwise available,
pursuant to sections 776(a)–(b) of the
Act.6 A detailed discussion of our
application of adverse facts available
was provided in the Preliminary
Decision Memorandum accompanying
our Preliminary Determination, and
additional discussion is contained in
the Issues and Decision Memorandum
accompanying this notice.
Changes Since the Preliminary
Determination
In our Preliminary Determination, we
applied adverse facts available to
calculate the subsidy rates for all
mandatory respondents. We have made
no changes to our analysis, or to the
respondents’ subsidy rates, for this final
determination.
Final Determination
With respect to the ‘‘all-others’’ rate,
section 705(c)(5)(A)(ii) of the Act
provides that if the countervailing duty
rates established for all exporters and
producers individually investigated are
determined entirely in accordance with
section 776 of the Act, Commerce may
use any reasonable method to establish
an all-others rate for exporters and
producers not individually investigated.
In this case, the rates assigned to
Fuyang, Hongyu Chemical, Kaison, and
6 See sections 776(a) and (b) of the Act. Section
782(i) of the Act requires Commerce to verify a
respondent’s data as part of an investigation.
However, because we applied adverse facts
available to each of the respondents in the
Preliminary Determination, we did not conduct
verification in this investigation.
E:\FR\FM\21SEN1.SGM
21SEN1
Agencies
[Federal Register Volume 83, Number 184 (Friday, September 21, 2018)]
[Notices]
[Pages 47876-47879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20606]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
International Trade Administration
[A-570-071]
Sodium Gluconate, Gluconic Acid, and Derivative Products From the
People's Republic of China: Final Affirmative Determination of Sales at
Less Than Fair Value
AGENCY: Enforcement and Compliance, International Trade Administration,
Department of Commerce.
SUMMARY: The Department of Commerce (Commerce) determines that sodium
gluconate, gluconic acid, and derivative products from the People's
Republic of China (China) are being sold in the United States at less
than fair value (LTFV).
DATES: Applicable September 21, 2018.
FOR FURTHER INFORMATION CONTACT: Magd Zalok or Stephen Bailey, AD/CVD
Operations, Office IV, Enforcement and Compliance, International Trade
Administration, U.S. Department of Commerce, 1401 Constitution Avenue
NW, Washington, DC 20230; telephone: (202) 482-4162 or (202) 482-0193,
respectively.
SUPPLEMENTARY INFORMATION:
Background
This final determination is made in accordance with section 735(a)
of the Tariff Act of 1930, as amended (the Act). On July 10, 2018,
Commerce published in the Federal Register its preliminary affirmative
determination of sales at LTFV investigation of sodium gluconate,
gluconic acid, and derivative products from China.\1\ We invited
interested parties to comment on the Preliminary Determination. On
August 9, 2018, we received a case brief from PMP Fermentation
Products, Inc., the petitioner in this investigation. We received no
comments from other interested parties.
---------------------------------------------------------------------------
\1\ See Sodium Gluconate, Gluconic Acid, and Derivative Products
from the People's Republic of China: Preliminary Determination of
Sales at Less Than Fair Value, 83 FR 31949 (July 10, 2018)
(Preliminary Determination) and accompanying Preliminary Decision
Memorandum.
---------------------------------------------------------------------------
For a complete description of the events that followed the
Preliminary Determination, as well as a full discussion of the issues
raised by parties for this final determination, see the Issues and
Decision Memorandum that is dated concurrently with this determination
and hereby adopted by this notice.\2\ The Issues and Decision
Memorandum is a public document and is on file electronically via
Enforcement and Compliance's Antidumping and Countervailing Duty
Centralized Electronic Service System (ACCESS). ACCESS is available to
registered users at https://access.trade.gov, and is available to all
parties in the Central Records Unit, Room B8024 of the main Department
of Commerce building. In addition, a complete version of the Issues and
Decision Memorandum can be accessed directly at https://enforcement.trade.gov/frn/. The signed Issues and Decision Memorandum
and the electronic version are identical in content.
---------------------------------------------------------------------------
\2\ See Memorandum, ``Issues and Decision Memorandum for the
Final Affirmative Determination in the Less-Than-Fair-Value
Investigation of Sodium Gluconate, Gluconic Acid, and Derivative
Products from the People's Republic of China'' (Issues and Decision
Memorandum).
---------------------------------------------------------------------------
Scope of the Investigation
The products covered by this investigation are sodium gluconate,
gluconic acid, and derivative products from China. For a complete
description of the scope of this investigation, see Appendix I to this
notice.
No interested party commented on the scope published in the
Preliminary Determination. Thus, Commerce has made no changes to the
scope of the investigation from that published in the Initiation Notice
and Preliminary Determination.\3\
---------------------------------------------------------------------------
\3\ See Sodium Gluconate, Gluconic Acid, and Derivative Products
from France and the People's Republic of China: Initiation of Less-
Than-FairValue Investigations, 83 FR 516 (January 4, 2018)
(Initiation Notice); Preliminary Determination, 83 FR at 31949 and
accompanying Preliminary Decision Memorandum at 5-6.
---------------------------------------------------------------------------
Period of Investigation
The period of investigation is April 1, 2017, through September 30,
2017.
Analysis of Comments Received
All issues raised in the case brief that was submitted by the
petitioner in this investigation are addressed in the Issues and
Decision Memorandum. A list of the issues addressed in the Issues and
Decision Memorandum is attached to this notice at Appendix II.
China-Wide Entity
For the reasons explained in the Preliminary Determination, we are
continuing to find that the use of adverse facts available (AFA),
pursuant to sections 776(a) and (b) of the Act, is appropriate and are
applying a rate based entirely on AFA to the China-wide entity.\4\ The
China-wide entity includes Shandong Fuyang Biotechnology Co., Ltd./
Shandong Fuyang Biology Starch Co., Ltd.
[[Page 47877]]
(Shandong Fuyang),\5\ Qingdao Dongxiao Enterprise Co., Ltd. (Qingdao
Dongxiao),\6\ Zhejiang Tianyi Food Additives Co., Ltd. (Tianyi
Food),\7\ and Dezhou Huiyang Biotechnology Co., Ltd. (Dezhou
Huiyang).\8\ These companies failed to respond to Commerce's requests
for information and withdrew from participation in this investigation.
As these non-responsive companies did not demonstrate that they are
eligible for separate rate status, Commerce continues to consider them
to be part of the China-wide entity. Consequently, we continue to find
that the China-wide entity, which includes these non-responsive
companies, withheld requested information, significantly impeded this
proceeding and failed to cooperate to the best of its ability.
---------------------------------------------------------------------------
\4\ See Preliminary Decision Memorandum at 11.
\5\ See Memorandum, ``Less-Than-Fair-Value Investigation of
Sodium Gluconate, Gluconic Acid, and Derivative Products from the
People's Republic of China: Respondent Selection,'' dated January
17, 2018 (Initial Respondent Selection Memorandum). See also
Shandong Fuyang letter, ``Notice of Non-Participation in
Investigation,'' dated March 30, 2018.
\6\ See Qingdao Dongxiao's Letter, ``Withdrawal from
Participation,'' dated February 14, 2018.
\7\ See Tianyi Food, see Commerce's Memorandum, ``Selection of
Additional Respondent,'' dated March 5, 2018 and Tianyi Food's
Letter, ``Withdrawal from Participation,'' dated March 8, 2018.
\8\ See Dezhou Huiyang's Commerce's Memorandum, ``Selection of
Additional Respondent,'' dated March 9, 2018 and Dezhou Huiyang's
Letter, ``Dezhou Huiyang Biotechnology Co., Ltd. Withdrawal of
Participation in Antidumping Duty Investigation,'' dated March 13,
2018.
---------------------------------------------------------------------------
China-Wide Rate
In selecting the AFA rate for the China-wide entity, Commerce's
practice is to select a rate that is sufficiently adverse to ensure
that the uncooperative party does not obtain a more favorable result by
failing to cooperate than if it had fully cooperated.\9\ Specifically,
it is Commerce's practice to select, as an AFA rate, the higher of: (a)
The highest dumping margin alleged in the petition; or (b) the highest
calculated dumping margin of any respondent in the investigation.\10\
There are no respondents for which we are calculating a separate
dumping margin for the final determination. Thus, the highest (and
only) rate on the record of the proceeding is the rate found in the
Petition,\11\ which is the only information reasonably at Commerce's
disposal to determine a rate that is sufficiently adverse to induce
cooperation.\12\
---------------------------------------------------------------------------
\9\ See Statement of Administrative Action accompanying the
Uruguay Round Agreements Act, H.R. Rep. No. 103-316 at 870 (1994)
(H.R. Rep 103-316), reprinted in 1994 U.S.C.A.A.N.
\10\ See Silicon Metal from Australia: Affirmative Final
Determination of Sales at Less Than Fair Value and Final Affirmative
Determination of Critical Circumstances in Part, 83 FR 9839 (March
8, 2018) and accompanying Issues and Decision Memorandum at Comment
1.
\11\ See Petitioner's Letter, ``Petition for Antidumping and
Countervailing Duties: Sodium Gluconate, Gluconic Acid, and
Derivative Products from the People's Republic of China and France''
(November 30, 2017) (the Petition).
\12\ See, e.g., Certain Hardwood Plywood Products from the
People's Republic of China: Preliminary Affirmative Determination of
Sales at Less Than Fair Value, Preliminary Affirmative Determination
of Critical Circumstances, in Part, 82 FR 28629 (June 23, 2017) and
accompanying Preliminary Decision Memorandum at pages 31-32 (revised
in Certain Hardwood Plywood Products from the People's Republic of
China: Final Determination of Sales at Less Than Fair Value, and
Final Affirmative Determination of Critical Circumstances, in Part,
82 FR 53460 (November 16, 2017) because Commerce calculated a higher
rate than the highest Petition rate to apply as the AFA rate)).
---------------------------------------------------------------------------
Thus, as AFA, Commerce assigned to the China-wide entity the rate
of 213.15 percent, which is the sole dumping margin alleged in the
Petition.\13\
---------------------------------------------------------------------------
\13\ See Petitioner's letter, ``Petition for Antidumping and
Countervailing Duties: Sodium Gluconate, Gluconic Acid, and
Derivative Products from the People's Republic of China and
France,'' dated November 30, 2017 (the Petitions),
Sodium Gluconate, Gluconic Acid, and Derivative Products from
France and the People's Republic of China: Initiation of Less-Than-
Fair-Value Investigations, 83 FR 516 (January 4, 2018) (Initiation
Notice), and Antidumping Duty Investigation Initiation Checklist:
Sodium Gluconate, Gluconic Acid, and Derivative Products from the
People's Republic of China, dated December 20, 2017 (China AD
Initiation Checklist).
---------------------------------------------------------------------------
Separate Rates
For the final determination, we continue to find that the evidence
placed on the record of this investigation by Anhui Xingzhou Medicine
Food Co., Ltd. (Xingzhou Medicine) \14\ demonstrates an absence of de
jure and de facto government control. Accordingly, consistent with its
Preliminary Determination, Commerce assigned Xingzhou Medicine a
separate rate, which is the petition rate, because it is the only rate
available on the record of this proceeding. For a full description of
the methodology underlying Commerce's final determination, see the
Issues and Decision Memorandum.
---------------------------------------------------------------------------
\14\ See, e.g., Xingzhou Medicine's Letter, ``Xingzhou Medicine
Separate Rate Application,'' dated February 5, 2018; Commerce's
Letter, ``1st Supplemental Questionnaire Regarding the Separate Rate
Application for Anhui Xingzhou Medicine Food Co., Ltd.,'' dated
February 27, 2018; Xingzhou Medicine's Letter, ``Supplemental SRA
Questionnaire Response,'' dated March 6, 2018; Commerce's Letter,
``2nd Supplemental Questionnaire regarding the Separate Rate
Application for Anhui Xingzhou Medicine Food Co., Ltd.,'' dated
March 22, 2018. and Xingzhou Medicine's Letter, ``Second
Supplemental SRA Questionnaire Response,'' dated March 29, 2018.
---------------------------------------------------------------------------
Combination Rates
In the Initiation Notice, Commerce stated that it would calculate
producer/exporter combination rates for the respondents that are
eligible for a separate rate in this investigation.\15\ Policy Bulletin
05.1 describes this practice.\16\ Because Commerce determined that the
mandatory respondents originally selected are not eligible for separate
rate status and, thus, should be considered part of the China-wide
entity and assigned, as AFA, the petition rate to the China-wide
entity, Commerce did not calculate producer/exporter combination rates
for those respondents.
---------------------------------------------------------------------------
\15\ See Initiation Notice, 83 FR 516.
\16\ See Enforcement and Compliance's Policy Bulletin No. 05.1,
regarding, ``Separate-Rates Practice and Application of Combination
Rates in Antidumping Investigations involving Non-Market Economy
Countries,'' (April 5, 2005) (Policy Bulletin 05.1), available on
Commerce's website at https://enforcement.trade.gov/policy/bull05-1.pdf.
\17\ The China-wide Entity includes Dezhou Huiyang, Qingdao
Dongxiao, Shandong Fuyang, and Tianyi Food.
---------------------------------------------------------------------------
Final Determination
Commerce determines that sodium gluconate, gluconic acid, and
derivative products from China are being, or are likely to be, sold in
the United States at LTFV, and that the following dumping margins
exist:
------------------------------------------------------------------------
Estimated
weighted-
Exporter Producer average
dumping margin
(percent)
------------------------------------------------------------------------
Anhui Xingzhou Medicine Food Co., Xiwang 213.15
Ltd. Pharmaceutical Co.,
Ltd.
Anhui Xingzhou Medicine Food Co., Zhucheng Shuguang 213.15
Ltd. Biotech Co., Ltd.
China-wide Entity \17\............ .................... 213.15
------------------------------------------------------------------------
[[Page 47878]]
Disclosure
Normally, Commerce discloses to interested parties the calculations
performed in connection with a final determination within five days of
any public announcement or, if there is no public announcement, within
five days of the date of publication of the notice of final
determination in the Federal Register, in accordance with 19 CFR
351.224(b). However, because Commerce applied AFA to the China-wide
entity (which includes the companies subject to individual examination)
in this investigation, in accordance with section 776 of the Act, and
the applied AFA rate is based solely on the Petition, there are no
calculations to disclose.
Continuation of Suspension of Liquidation
In accordance with section 735(c)(1)(B) of the Act, we will direct
U.S. Customs and Border Protection (CBP) to continue to suspend
liquidation of all entries of sodium gluconate, gluconic acid, and
derivative products from China, as described in Appendix I of this
notice, which are entered, or withdrawn from warehouse, for consumption
on or after July 10, 2018, the date of publication in the Federal
Register of the affirmative Preliminary Determination.
Further, pursuant to section 735(c)(1)(B)(ii) of the Act, Commerce
will instruct CBP to collect a cash deposit as follows: (1) The rate
for the exporters listed in the chart above will be the rate we have
determined in this final determination; (2) for all Chinese exporters
of subject merchandise which have not received their own rate, the
cash-deposit rate will be the China-wide rate; and (3) for all non-
Chinese exporters of subject merchandise which have not received their
own rate, the cash-deposit rate will be the rate applicable to the
Chinese exporter/producer combination that supplied that non-Chinese
exporter. These suspension-of-liquidation instructions will remain in
effect until further notice. Because there has been no demonstration
that an adjustment for domestic subsidies is warranted, Commerce has
not made any such adjustment to the rate assigned to Xingzhou Medicine
or the China-wide entity. Additionally, Commerce is making no
adjustments for export subsidies to the antidumping cash deposit rate
in this investigation because we have made no findings in the companion
countervailing duty investigation that any of the programs are export
subsidies.\18\
---------------------------------------------------------------------------
\18\ See Sodium Gluconate, Gluconic Acid and Derivative Products
from the People's Republic of China: Preliminary Affirmative
Countervailing Duty Determination and Alignment of Final
Determination With Final Antidumping Duty Determination, 83 FR 23888
(May 23, 2018) (Preliminary Affirmative CVD Determination) and
accompanying Preliminary Determination Memorandum at 19 (``As AFA,
pursuant to section 776(a) and (b), Commerce is finding all programs
initiated upon in this proceeding to be countervailable--that is,
they provide a financial contribution within the meaning of sections
771(5)(B)(i) and (D) of the Act, confer a benefit within the meaning
of section 771(5)(B) of the Act, and are specific within the meaning
of section 771(5A) of the Act. Accordingly, all programs are
included in Commerce's calculation of an AFA rate for Fuyang, Hongyu
Chemical, Kaison, and Qingdao Dongxiao.'') (emphasis added). In the
final determination of the companion countervailing duty
investigation, Commerce made no changes to its analysis and
calculations of subsidy rates from the Preliminary Affirmative CVD
Determination. See Sodium Gluconate, Gluconic Acid and Derivative
Products from the People's Republic of China: Final Affirmative
Countervailing Duty Determination, and accompanying Issues and
Decision Memorandum.
---------------------------------------------------------------------------
International Trade Commission Notification
In accordance with section 735(d) of the Act, we intend to notify
the International Trade Commission (ITC) of the final affirmative
determination of sales at LTFV. As Commerce's final determination is
affirmative, in accordance with section 735(b)(2) of the Act, the ITC
will determine, within 45 days, whether the domestic industry in the
United States is materially injured, or threatened with material
injury, by reason of imports of sodium gluconate, gluconic acid, and
derivative products from China, or sales (or the likelihood of sales)
for importation, of sodium gluconate, gluconic acid, and derivative
products from China. If the ITC determines that such injury does not
exist, this proceeding will be terminated, and all securities posted
will be refunded or canceled. If the ITC determines that such injury
does exist, Commerce intends to issue an antidumping duty order
directing CBP to assess, upon further instruction by Commerce,
antidumping duties on all imports of the subject merchandise entered,
or withdrawn from warehouse, for consumption on or after the effective
date of the suspension of liquidation.
Notification Regarding Administrative Protective Orders
This notice will serve as a reminder to the parties subject to
administrative protective order (APO) of their responsibility
concerning the disposition of propriety information disclosed under APO
in accordance with 19 CFR 351.305. Timely written notification of
return or destruction of APO materials or conversion to judicial
protective order is hereby requested. Failure to comply with the
regulations and terms of an APO is a sanctionable violation.
We intend to issue and publish this determination in accordance
with sections 735(d) and 777(i)(1) of the Act.
Dated: September 17, 2018.
Gary Taverman,
Deputy Assistant Secretary for Antidumping and Countervailing Duty
Operations, performing the non-exclusive functions and duties of the
Assistant Secretary for Enforcement and Compliance.
Appendix I
Scope of the Investigation
The scope of the investigation covers all grades of sodium
gluconate, gluconic acid, liquid gluconate, and glucono delta
lactone (GDL) (collectively GNA Products), regardless of physical
form (including, but not limited to substrates; solutions; dry
granular form or powders, regardless of particle size; or as a
slurry). The scope also includes GNA Products that have been blended
or are in solution with other product(s) where the resulting mix
contains 35 percent or more of sodium gluconate, gluconic acid,
liquid gluconate, and/or GDL by dry weight.
Sodium gluconate has a molecular formula of
NaC6H11O7. Sodium gluconate has a
Chemical Abstract Service (CAS) registry number of 527-07-1, and can
also be called ``sodium salt of gluconic acid'' and/or sodium 2, 3,
4, 5, 6 pentahydroxyhexanoate. Gluconic acid has a molecular formula
of C6H12O7. Gluconic acid has a CAS
registry number of 526-95-4, and can also be called 2, 3, 4, 5, 6
pentahydroxycaproic acid. Liquid gluconate is a blend consisting
only of gluconic acid and sodium gluconate in an aqueous solution.
Liquid gluconate has CAS registry numbers of 527-07-1, 526-95-4, and
7732-18-5, and can also be called 2, 3, 4, 5, 6-pentahydroxycaproic
acid-hexanoate. GDL has a molecular formula of
C6H10O6. GDL has a CAS registry
number of 90-80-2, and can also be called d-glucono-1,5-lactone.
The merchandise covered by the scope of the investigation is
currently classified in the Harmonized Tariff Schedule of the United
States (HTSUS) under subheadings 2918.16.1000, 2918.16.5010, and
2932.20.5020. Merchandise covered by the scope may also enter under
HTSUS subheadings 2918.16.5050, 3824.99.2890, and 3824.99.9295.
Although the HTSUS subheadings and CAS registry numbers are provided
for convenience and customs purposes, the written description of the
merchandise is dispositive.
Appendix II
List of Topics Discussed in the Issues and Decision Memorandum
I. Summary
II. List of Issues
III. Background
IV. Scope of Investigation
[[Page 47879]]
V. Discussion of the Issues
Comment 1: Application of Adverse Facts Available (AFA) to the
China-wide Entity
Comment 2: Whether to Assign the China-Wide Entity Rate to the
Separate Rate Applicant
Comment 3: Whether the Scope of the Investigation Should be
Modified
VI. Recommendation
[FR Doc. 2018-20606 Filed 9-20-18; 8:45 am]
BILLING CODE 3510-DS-P